Login

Financial Snapshot

Revenue
TTM
$87.87K
Gross Margin
TTM
-832.02%
Net Income
TTM
-$12.22M
Current Assets
2025 Q3
$4.149M
Current Liabilities
2025 Q3
$365.5K
Current Ratio
2025 Q3
1135.27%
Total Assets
2025 Q3
$5.715M
Total Liabilities
2025 Q3
$403.1K
Book Value
2025 Q3
5.312M
Cash
Last 4 Quarters
N/A
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$11.31M

Stock Price

Loading...
Market Cap: $3.77 Million

About Virax Biolabs Group Ltd

Virax Biolabs Group Ltd. is a holding company, which engages in the sale, distribution, and marketing of diagnostics test kits and med-tech and personal protective equipment products for the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest in the field of immunology. The firm is engaged in developing ViraxImmune with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against global viral diseases as well as helping with the early diagnosis of post-viral syndromes associated with T cell exhaustion and chronic inflammation. Its product portfolio includes ViraxClear and ViraxVet. ViraxClear offers a range of accurate diagnostic testing kits and machines. ViraxVet offers various rapid and molecular tests for small animal veterinary diagnostics. The firm is initially focused on diseases associated with post-viral syndromes, including SARS-CoV-2, Human Papillomavirus (HPV), Malaria, Hepatitis B, and Herpes (HSV-1).

Industry: In Vitro & In Vivo Diagnostic Substances

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support